Diabetes Journey

Diabetes Journey supports healthcare professionals (HCPs) in the treatment of patients with type 2 diabetes.

The product is a decision support service, that offers objective recommendations on the most efficacious medications for the HCP to consider.

The project was developed for a global pharmaceutical company all the way from concept creation to launch in Southeast Asia.

Diabetes is a chronic disease that occurs when the pancreas is no longer able to make insulin, or when the body cannot make good use of the insulin it produces. In 2019 an approximate of 463 million adults (20-79 years) were living with diabetes; by 2045 this number will rise to 700 million1.

Diabetes is often referred to as a global pandemic. The disease is one of the fastest growing health challenges of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years2.

Delayed Injection Initiation

Less than 7% of all people with diabetes achieve their desired outcomes3. This is due to a multitude of reasons including, compliance, motivation, education, cost of medication and suboptimal medication regimen. Personalizing the treatment of diabetes is a known challenge and daily struggle of physicians. Guidelines published by ADA and EASD are complex and personalizing the treatment is a challenging exercise. For HCPs with less than 10-15 minutes per patient adhering to the guidance can prove an insurmountable task.

Intensification of the medication regimen is generally too slow. 31% of patients on 2nd line OADs are not in control of their diabetes4. For patients on a Sulfonylurea + Metformin combo it takes up to 5 years to intensify the treatment with other glucose-lowering treatments, even in the presence of elevated HbA1c5.

HCPs have only 10-15 minutes per patient.

Less than 7% of patients achieve the desired treatment outcomes.

Sub-optimal treatment increases costs by a factor of 2 to 4.

Empowering Physicians to Enhance the Treatment of Diabetes

Diabetes Journey is available both as a web and mobile application for iOS and Android. The app has launched in Vietnam and Bangladesh and directly supports the HCP to personalize the treatment of their patients.

The app is the worlds first model-based digitalized diabetes guideline, offering objective recommendations on the best medications for the HCP to consider.

How Does Diabetes Journey Work?

Enter Patient Details

The physician enters biomarkers about the patient, for the recommendation engine to process. Biomarkers include blood glucose measurements, kidney function, co-morbidities, current treatment, intolerated drugs, and the target blood glucose value.

Review Recommendations

The engine generates a list of treatment recommendations, based on the provided patient biomarkers, for the physician to consider. Namely what medications to initiate or discontinue and how to titrate prescribed medications.

Personalize Treatment

Based on the physician's decisions, a personalized treatment plan is presented. Easily printable and ready to administer – improving the treatment of the patient.

Fighting a Global Pandemic

Uncontrolled patients with diabetes are associated with big consequences. For society, treatment inefficiencies increases total treatment costs by a factor of 2 to 4 depending on the severity of the complications6. Patients risk acceleration of their diabetes, which effectively leads to higher levels of comorbidities, complications and decreased quality of life. Diabetes Journey and the sponsor behind the project is actively fighting these challenges and changing diabetes through digital interventions that save lives.

Endorsement by Public Officials, KOLs and MoH

To ensure objectivity, Diabetes Journey is developed in close collaboration with the Ministry of Health (MoH), public officials and local Key Opinion Leaders (KOLs) in all its respective markets.

Under the Hood

For the development of Diabetes Journey, Dawn Health has configured a sophisticated and powerful decision support engine called Bonsai. The engine is able to consume any static guideline data and clinical evidence across all chronic diseases and output a recommendation to the HCP.

In the Media

DISEASE AREA

Type 2 Diabetes

TARGET MARKETS

  • Bangladesh
  • Vietnam

DISEASE AREA

Type 2 Diabetes

TARGET MARKETS

  • Bangladesh
  • Vietnam

CAPABILITIES

  • Research
  • UX/UI Design
  • Back-End
  • Front-End
  • Android
  • iOS
  • Web
  1. https://diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html
  2. https://diabetesatlas.org/en/sections/worldwide-toll-of-diabetes.html
  3. http://www.citieschangingdiabetes.com
  4. IMS Disease Analyzer Germany 2016
  5. Brown et al. Diabetes Care 2004;75:1535–40
  6. Liebl, A., Neiss, A., Spannheimer, A., Reitberger, U., Wagner, T., & Görtz, A. (2001). Costs of type 2 diabetes in Germany. Results of the CODE-2 study. Deutsche medizinische Wochenschrift (1946), 126(20), 585-589.

Interested in working with us?

Get in touch
Get in touch